Abstract
Whether monoclonal antibodies are able to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern has been investigated using pseudoviruses. In this study we show that bamlanivimab, casirivimab, and imdevimab efficiently neutralize authentic SARS-CoV-2, including variant B.1.1.7 (alpha), but variants B.1.351 (beta) and P.2 (zeta) were resistant against bamlanivimab and partially resistant to casirivimab. Whether antibodies are able to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantshas been investigated using pseudoviruses. We show that authentic SARS-CoV-2 carrying E484K were resistant against bamlanivimab and less susceptible to casirivimab, convalescent and vaccine-elicited sera.
Keywords: SARS-CoV-2; bamlanivimab; casirivimab; convalescent; coronavirus; imdevimab; monoclonal antibodies; vaccination.
【저자키워드】 SARS-CoV-2, coronavirus, vaccination, monoclonal antibodies, bamlanivimab, Casirivimab, Imdevimab, convalescent, 【초록키워드】 coronavirus, vaccination, antibody, B.1.351, monoclonal antibody, variant, variants of concern, severe acute respiratory syndrome Coronavirus, monoclonal antibodies, variants, bamlanivimab, Casirivimab, Imdevimab, B.1.1.7, sera, Alpha, P.2, E484K, Beta, respiratory, convalescent, monoclonal, pseudoviruses, (Beta, (Alpha), acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, Zeta, susceptible, neutralize, investigated, less, 【제목키워드】 coronavirus, coronavirus 2, Carrying, Limited,